Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC,...

58

Transcript of Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC,...

Page 1: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 2: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 3: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 4: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 5: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 6: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 7: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 8: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 9: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 10: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 11: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 12: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 13: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 14: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 15: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 16: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 17: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 18: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 19: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 20: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 21: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 22: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 23: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 24: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 25: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 26: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 27: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 28: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 29: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 30: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 31: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 32: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 33: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 34: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 35: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 36: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 37: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 38: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 39: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 40: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 41: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 42: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 43: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 44: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 45: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 46: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 47: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 48: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 49: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 50: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 51: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 52: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 53: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 54: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 55: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 56: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 57: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over
Page 58: Associazione Medici Endocrinologi€¦ · 417 patients with metastatic, RAI-resistant DTC, progression last 14 months Randomization: Sorafenib 400 mg x 2 or placebo (cross-over) Cross-over

OPTIMIS - Global Observational Study on the use of Sorafenib … · OPTIMIS study design ClinicalTrials.gov NCT01933945 *Includes patients treated with sorafenib at a later time point

OPTIMIS - Global Observational Study on the use of Sorafenib … · OPTIMIS study design ClinicalTrials.gov NCT01933945 *Includes patients treated with sorafenib at a later time point

Evaluation of sorafenib for advanced hepatocellular carcinoma … · Sorafenib (Nexavar; Bayer Healthcare, Leverkusen, Ger-many) is an oral multi-targeted tyrosine kinase inhibitor

Evaluation of sorafenib for advanced hepatocellular carcinoma … · Sorafenib (Nexavar; Bayer Healthcare, Leverkusen, Ger-many) is an oral multi-targeted tyrosine kinase inhibitor

Milciclib and sorafenib synergistically downregulate c-Myc to … · 2020. 9. 17. · Jindal A (2020) Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor

Milciclib and sorafenib synergistically downregulate c-Myc to … · 2020. 9. 17. · Jindal A (2020) Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by … · Cancer Biology and Signal Transduction Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by … · Cancer Biology and Signal Transduction Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by

Australian public assessment report for Sorafenib › ... › files › auspar-sorafenib-140806.pdfAustralian Public Assessment Report for Sorafenib Proprietary Product Name: Nexavar

Australian public assessment report for Sorafenib › ... › files › auspar-sorafenib-140806.pdfAustralian Public Assessment Report for Sorafenib Proprietary Product Name: Nexavar

Sorafenib versus Transarterial chemoembolization for ...

Sorafenib versus Transarterial chemoembolization for ...

Enhanced sensitivity to sorafenib by inhibition of Akt1 ...file2.selleckchem.com/citations/A-674563-Hum-Cell-20150625.pdf · RESEARCH ARTICLE Enhanced sensitivity to sorafenib by

Enhanced sensitivity to sorafenib by inhibition of Akt1 ...file2.selleckchem.com/citations/A-674563-Hum-Cell-20150625.pdf · RESEARCH ARTICLE Enhanced sensitivity to sorafenib by

5‑fluorouracil enhances the antitumor effect of sorafenib ...

5‑fluorouracil enhances the antitumor effect of sorafenib ...

Treatment with low-dose sorafenib in combination with a ...

Treatment with low-dose sorafenib in combination with a ...

TDM du Sorafenib - OncoRésonanceoncoresonance.fr/gpco/wp-content/uploads/2016/12/Benoit-Blanchet-GPCO16-2.pdf · regression analysis indicated that sorafenib exposure was related

TDM du Sorafenib - OncoRésonanceoncoresonance.fr/gpco/wp-content/uploads/2016/12/Benoit-Blanchet-GPCO16-2.pdf · regression analysis indicated that sorafenib exposure was related

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

Biological evaluation of a novel sorafenib analogue, t‑CUPMAbstract Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular

SoLAT (Sorafenib Lenvatinib alternating treatment): a new … · 2018-10-04 · treatment protocol, SoLAT, using sorafenib and lenvatinib alternatively on refractory thyroid cancer.

SoLAT (Sorafenib Lenvatinib alternating treatment): a new … · 2018-10-04 · treatment protocol, SoLAT, using sorafenib and lenvatinib alternatively on refractory thyroid cancer.

Sorafenib Side effects and dose adjustment · Sorafenib-Side effects and dose adjustment - Adverse events: prevention and management as key • Patients should be informed to: –

Sorafenib Side effects and dose adjustment · Sorafenib-Side effects and dose adjustment - Adverse events: prevention and management as key • Patients should be informed to: –

Sequence‑dependent effect of sorafenib in combination with ...

Sequence‑dependent effect of sorafenib in combination with ...

Lenvatinib and sorafenib for treating differentiated ...

Lenvatinib and sorafenib for treating differentiated ...

2015 Advances in Hepatocellular Carcinoma Sorafenib-based ...€¦ · process like the later vascular maturation stage. Thus combining dalantercept and sorafenib may achieve enhanced

2015 Advances in Hepatocellular Carcinoma Sorafenib-based ...€¦ · process like the later vascular maturation stage. Thus combining dalantercept and sorafenib may achieve enhanced

Pericytes Elicit Resistance to Vemurafenib and Sorafenib ... · Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFb1 Axis Alessandro

Pericytes Elicit Resistance to Vemurafenib and Sorafenib ... · Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFb1 Axis Alessandro

Clinical Policy: Sorafenib (Nexavar)€¦ · Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.19 Line of Business: Commercial,

Clinical Policy: Sorafenib (Nexavar)€¦ · Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.19 Line of Business: Commercial,

Theranostics · Web viewAll these 119 patients received mono sorafenib therapy or systemic therapy containing sorafenib; according to NCCN guidelines for advanced hepatobiliary cancers

Theranostics · Web viewAll these 119 patients received mono sorafenib therapy or systemic therapy containing sorafenib; according to NCCN guidelines for advanced hepatobiliary cancers

Australian public assessment report for Sorafenib · Web viewAustralian Public Assessment Report for Sorafenib Proprietary Product Name: Nexavar Sponsor: Bayer Australia Ltd About

Australian public assessment report for Sorafenib · Web viewAustralian Public Assessment Report for Sorafenib Proprietary Product Name: Nexavar Sponsor: Bayer Australia Ltd About